Wolters Kluwer

Slight revisions to the outlook overshadow the good Q3 results

30/10/24 -"Wolters Kluwer released impressive 9M results, with continuous strong organic revenue growth and profitability figures. However, although the guidance was reiterated at the group level, Health ..."

PDF page sample
Pages
62
Language
English
Published on
30/10/24
Download
You may also be interested by these reports :
23/10/25
RELX released 9M figures in line with our expectations, confirming (for now) our theory that RELX is a winner of the GenAI technology. Moreover, ...
22/10/25
Definitely, investors struggle to make up their minds on Wolters Kluwer’s (BUY; Netherlands) status when it comes to Gen AI technology. Since our ...
21/10/25
The target price is practically unchanged after fine-tuning our model. Publicis exceeded organic growth expectations in Q3, raising full-year ...
17/10/25
Definitively, investors struggle to make up their minds on Wolters Kluwer (BUY ; Netherlands) status when it relates to Gen AI technology. Since ...

EXECUTIVE SUMMARY

Updates Pension Risks
Target & Opinion Governance & Management
Business & Trends Graphics : Momentum
Money Making Graphics : MACD & Volumes
Debt Graphics : Sensitivities
Valuation Sector: Performance
DCF Sector: Key data
NAV/SOTP Sector: Ratios & Valorisation
Worth knowing Sector: Peers
Financials Sector: Analysis

CONFLICTS OF INTEREST

AlphaValue does not have nor seek any business with companies covered in AlphaValue Research paid by subscription. As a result, investors can be confident that there is no conflict of interest that could affect the objectivity of AlphaValue Research.

Corporate broking NO
Trading in corporate shares NO
Analyst ownership NO
Advising of corporate (strategy, marketing, debt, etc) NO
Research paid for by corporate NO
Provision of corporate access paid for by corporate NO
Link between and a banking entity NO
Brokerage activity at AlphaValue NO